Drug Database · Clinicians

Fludarabine

Brands (2) Fludara, FludaraccordShow all

US brand (reference label): Fludarabine Phosphate; not a Philippine-registered brand.

Antineoplastic (purine analogue) PH FDA category

Rx · Prescription drug2 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 291f6ee2-f5d2-ae6c-e063-6294a90a5951, version date September 20, 2026 (Fludarabine Phosphate · Hisun Pharmaceuticals USA, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); for the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed…
  • for the treatment of adults with B-cell CLL who have not responded to, or whose disease has progressed during treatment with at least one alkylating- agent containing regimen.
US FDA label
Full indications and usage US FDA label

Fludarabine Phosphate Injection is indicated: as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); for the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed during treatment with at least one alkylating-agent containing regimen. Fludarabine Phosphate Injection is a nucleoside metabolic inhibitor indicated: as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); (1) for the treatment of adults with B-cell CLL who have not responded to, or whose disease has progressed during treatment with at least one alkylating- agent containing regimen.

(1)

Contraindications

None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • The recommended dosage is: In Combination with Cyclophosphamide and Rituximab: The recommended dosage is 25 mg/m 2 administered intravenously over 30 minutes daily for the first three days (Days 1 to 3) of each 28-day cycle for 6 cycles in combination with cyclophosphamide 250 mg/m 2 administered intravenously daily for three days (Days 1 to 3), and rituximab 375 mg/m 2 administered intravenously on Day 1 of the first cycle, followed by rituximab 500 mg/m 2 on Day 1 of subsequent cycles. (2.1)
  • Single Agent: The recommended dosage is 25 mg/m 2 administered intravenously over approximately 30 minutes daily for five consecutive days (Days 1 to 5) of each 28-day cycle. (2.1)
  • Renal impairment: Reduce the dosage for patients with creatinine clearance (CLcr) 30 to 79 mL/min. (2.2, 8.6)
  • See the Full Prescribing Information for instructions for preparation and administration. (2.3)
2.1 Recommended Dosage

2.1 Recommended Dosage In Combination with Cyclophosphamide and Rituximab The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m 2 administered intravenously over 30 minutes daily for the first three days (Days 1 to 3) of each 28-day cycle for 6 cycles or until unacceptable toxicity or disease progression, in combination with cyclophosphamide 250 mg/m 2 administered intravenously daily for three days (Days 1 to 3), and rituximab 375 mg/m 2 administered intravenously on Day 1 of the first cycle, followed by rituximab 500 mg/m 2 on Day 1 of subsequent cycles. Refer to the cyclophosphamide and rituximab prescribing information for additional dosing information as appropriate.

Single Agent The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m 2 administered intravenously over 30 minutes daily for five consecutive days (Days 1 to 5) of each 28-day cycle.

2.2 Recommended Dosage for Patients with Renal Impairment

2.2 Recommended Dosage for Patients with Renal Impairment Reduce the Fludarabine Phosphate Injection dosage for patients with renal impairment as shown in Table 1. Closely monitor patients with renal impairment for adverse reactions. Table 1: Dosage Modifications for Renal Impairment Cre atinine Clearance (Estimated by Cockcroft-Gault equation) Recommended Dosage ​50 – 79 mL/min ​20 mg/m 2 30 – 49 mL/min 15 mg/m 2 < 30 mL/min A dosage has not been established.

2.3 Preparation and Administration

2.3 Preparation and Administration Fludarabine Phosphate Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Dilute Fludarabine Phosphate Injection in 100 mL to 125 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Infuse diluted Fludarabine Phosphate Injection intravenously over 30 minutes. Fludarabine Phosphate Injection contains no antimicrobial preservative. If not used immediately, discard the unused portion within 8 hours after opening the single-dose vial. Do not mix Fludarabine Phosphate Injection with other drugs.

2.1 Recommended Dosage

2.1 Recommended Dosage In Combination with Cyclophosphamide and Rituximab The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m 2 administered intravenously over 30 minutes daily for the first three days (Days 1 to 3) of each 28-day cycle for 6 cycles or until unacceptable toxicity or disease progression, in combination with cyclophosphamide 250 mg/m 2 administered intravenously daily for three days (Days 1 to 3), and rituximab 375 mg/m 2 administered intravenously on Day 1 of the first cycle, followed by rituximab 500 mg/m 2 on Day 1 of subsequent cycles. Refer to the cyclophosphamide and rituximab prescribing information for additional dosing information as appropriate.

Single Agent The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m 2 administered intravenously over 30 minutes daily for five consecutive days (Days 1 to 5) of each 28-day cycle.

2.2 Recommended Dosage for Patients with Renal Impairment

2.2 Recommended Dosage for Patients with Renal Impairment Reduce the Fludarabine Phosphate Injection dosage for patients with renal impairment as shown in Table 1. Closely monitor patients with renal impairment for adverse reactions. Table 1: Dosage Modifications for Renal Impairment Cre atinine Clearance (Estimated by Cockcroft-Gault equation) Recommended Dosage ​50 – 79 mL/min ​20 mg/m 2 30 – 49 mL/min 15 mg/m 2 < 30 mL/min A dosage has not been established.

2.3 Preparation and Administration

2.3 Preparation and Administration Fludarabine Phosphate Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Dilute Fludarabine Phosphate Injection in 100 mL to 125 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Infuse diluted Fludarabine Phosphate Injection intravenously over 30 minutes. Fludarabine Phosphate Injection contains no antimicrobial preservative. If not used immediately, discard the unused portion within 8 hours after opening the single-dose vial. Do not mix Fludarabine Phosphate Injection with other drugs.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations)

2.2 Recommended Dosage for Patients with Renal Impairment Reduce the Fludarabine Phosphate Injection dosage for patients with renal impairment as shown in Table 1. Closely monitor patients with renal impairment for adverse reactions. Table 1: Dosage Modifications for Renal Impairment Cre atinine Clearance (Estimated by Cockcroft-Gault equation) Recommended Dosage ​50 – 79 mL/min ​20 mg/m 2 30 – 49 mL/min 15 mg/m 2 < 30 mL/min A dosage has not been established.

2.2 Recommended Dosage for Patients with Renal Impairment Reduce the Fludarabine Phosphate Injection dosage for patients with renal impairment as shown in Table 1. Closely monitor patients with renal impairment for adverse reactions. Table 1: Dosage Modifications for Renal Impairment Cre atinine Clearance (Estimated by Cockcroft-Gault equation) Recommended Dosage ​50 – 79 mL/min ​20 mg/m 2 30 – 49 mL/min 15 mg/m 2 < 30 mL/min A dosage has not been established.

8.6 Renal Impairment Reduce the dosage in patients with CLcr 30 to 79 mL/min. A dosage has not been established for patients with severe renal impairment (CLcr < 30 mL/min) [see Dosage and Administration (2.2)]. The total body clearance of 2-fluoro-ara-A is correlated with the creatinine clearance [see Clinical Pharmacology (12.3)]; however, the effect of varying degrees of renal impairment on the pharmacokinetics of this metabolite has not been fully characterized.

  • Lactation: Advise not to breastfeed. (8.2)
  • Infertility: May impair fertility. (8.3) See 17 for PATIENT COUNSELING INFORMATION. Revised: 08/2025

Kidney-specific guidance from renalcarematters.com: in preparation.

Administration

2.3 Preparation and Administration Fludarabine Phosphate Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Dilute Fludarabine Phosphate Injection in 100 mL to 125 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Infuse diluted Fludarabine Phosphate Injection intravenously over 30 minutes. Fludarabine Phosphate Injection contains no antimicrobial preservative. If not used immediately, discard the unused portion within 8 hours after opening the single-dose vial. Do not mix Fludarabine Phosphate Injection with other drugs.

2.3 Preparation and Administration Fludarabine Phosphate Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Dilute Fludarabine Phosphate Injection in 100 mL to 125 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Infuse diluted Fludarabine Phosphate Injection intravenously over 30 minutes. Fludarabine Phosphate Injection contains no antimicrobial preservative. If not used immediately, discard the unused portion within 8 hours after opening the single-dose vial. Do not mix Fludarabine Phosphate Injection with other drugs.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 25 mg/mL(50 mg/2 mL
  • Powder for injection: 50 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Fludarabine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Fludarabine
Package insert
FludaraFludarabine phosphate
50 mg Powder for Injection (IV)Type I Clear Glass Vial (Box of 5's)
RxVAT-exempt
Baxter Oncology GmbHGermany
Importer: Sanofi-Aventis Philippines, Inc.
DR-XY26134
Mar 6, 2031
FludaraccordFludarabine (as phosphate)
25mg/mL(50mg/ 2mL) Solution for Injection (IM/IV)2mL USP Type I Clear Glass Vial with Rubber Stopper and Aluminum Flip-off Seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Ltd.- Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office
DRP-12236
Jun 30, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

Injection: 50 mg/2 mL (25 mg/mL). Fludarabine Phosphate Injection, USP is supplied as a clear, colorless to almost colorless sterile solution in single-dose vials. Injection: 50 mg/2 mL (25 mg/mL) (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • N eurological Toxicities: Coma, seizures, agitation and confusion can occur and are dose dependent. Monitor patients for signs and symptoms of neurologic toxicity. Consider delaying or discontinuing Fludarabine Phosphate Injection if neurotoxicity occurs. (5.1, 10) M y elosuppression: Severe anemia, thrombocytopenia, neutropenia, or pancytopenia can occur and are dose dependent. Monitor blood counts before and during treatment. Consider dose delays, dose reductions, or permanent discontinuation if recovery has not occurred by the first day of the next scheduled cycle. (5.2, 10) A u t o immune Cytopenias: Life-threatening and fatal autoimmune hemolytic anemia, autoimmune thrombocytopenia/ thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia can occur. Closely monitor patients for hemolysis and manage as clinically indicated. (5.3)
  • Transfusion-Associated Graft-Versus-Host Disease: Use only irradiated blood products for transfusions. (5.4)
  • Tumor Lysis Syndrome (TLS): Closely monitor patients at risk for TLS, consider appropriate prophylaxis including hydration, and manage as clinically indicated. (5.5)
  • P u lmonary Toxicity in Patients with CLL when Fludarabine Phosphate is Used with Pentostatin: Severe and sometimes fatal pulmonary toxicity when used concomitantly with pentostatin. Concomitant use is not recommended. (5.6, 7.1)
  • V accination …
5.1 Neurologic Toxicities

5.1 Neurologic Toxicities Severe central nervous system (CNS) adverse reactions, including coma, seizures, agitation and confusion, can occur in patients treated with Fludarabine Phosphate Injection. CNS adverse reactions may occur either early or late after the initiation of Fludarabine Phosphate Injection (range 7 to 225 days).

CNS adverse reactions are dose dependent and occur at greater incidence and severity in patients treated at doses higher than the recommended dose of Fludarabine Phosphate Injection [see Overdosage (10)]. Monitor patients for signs and symptoms of neurologic toxicity during and after treatment with Fludarabine Phosphate Injection.

Consider delaying or discontinuing Fludarabine Phosphate Injection if neurotoxicity occurs. Do not administer Fludarabine Phosphate Injection at doses higher than the recommended dose. Advise patients that Fludarabine Phosphate Injection may reduce the ability to drive or use mechanical equipment, since fatigue, weakness, visual disturbances, confusion, agitation, or seizures may occur.

5.2 Myelosuppression

5.2 Myelosuppression Fludarabine phosphate can cause severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia, or anemia. Cases of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported. The median time to nadir of counts was approximately 13 days (range, 3 to 25 days) for granulocytes and 16 days (range, 2 to 32 days) for platelets.

The duration of the cytopenia in reported cases has ranged from approximately 2 months to approximately 1 year. Monitor complete blood counts at baseline, prior to and during each treatment cycle, and as clinically needed. Consider dosage delays, dose reductions, or permanent discontinuation if recovery has not occurred by the first day of the next scheduled cycle.

5.3 Autoimmune Cytopenias

5.3 Autoimmune Cytopenias Life-threatening and fatal autoimmune hemolytic anemia, autoimmune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia can occur in patients treated with fludarabine phosphate with or without a previous history of autoimmune hemolytic anemia or a positive Coombs’ test. The majority of patients rechallenged with fludarabine phosphate developed a recurrence in the hemolytic process.

The mechanism(s) which predispose patients to the development of this complication has not been identified. Closely monitor patients during treatment with Fludarabine Phosphate Injection for autoimmune cytopenias and manage as clinically indicated.

5.4 Transfusion Associated Graft-Versus-Host Disease

5.4 Transfusion Associated Graft-Versus-Host Disease Transfusion-associated graft-versus-host disease has been observed after transfusion of non-irradiated blood in patients treated with fludarabine phosphate. Fatal outcome as a consequence of this disease has been reported. Therefore, to minimize the risk of transfusion-associated graft-versus-host disease, patients who require blood transfusion and who are undergoing, or who have received, treatment with Fludarabine Phosphate Injection should receive irradiated blood only.

5.5 Tumor Lysis Syndrome

5.5 Tumor Lysis Syndrome Tumor lysis syndrome (TLS) can occur in patients treated with Fludarabine Phosphate Injection. TLS has been reported in patients with CLL who have large tumor burdens and can occur as early as the first week of treatment. Closely monitor patients at risk for TLS, consider appropriate prophylaxis including hydration, and manage as clinically indicated.

5.6 Pulmonary Toxicity in Patients with CLL When

5.6 Pulmonary Toxicity in Patients with CLL When Fludarabine Phosphate is Used with Pentostatin In clinical trials, patients experienced fatal pulmonary toxicity when treated with fludarabine phosphate and pentostatin for refractory CLL. Avoid concomitant use of Fludarabine Phosphate Injection with pentostatin [see Drug Interactions (7.1)].

5.7 Vaccination

5.7 Vaccination During and after treatment with Fludarabine Phosphate Injection, avoid vaccination with live vaccines.

5.8 Embryo-Fetal Toxicity

5.8 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, Fludarabine Phosphate Injection can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of fludarabine phosphate to pregnant animals during organogenesis resulted in adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities at maternal doses below (rabbits) and above (rats) those in patients at the recommended human dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Fludarabine Phosphate Injection and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Fludarabine Phosphate Injection and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

5.1 Neurologic Toxicities

5.1 Neurologic Toxicities Severe central nervous system (CNS) adverse reactions, including coma, seizures, agitation and confusion, can occur in patients treated with Fludarabine Phosphate Injection. CNS adverse reactions may occur either early or late after the initiation of Fludarabine Phosphate Injection (range 7 to 225 days).

CNS adverse reactions are dose dependent and occur at greater incidence and severity in patients treated at doses higher than the recommended dose of Fludarabine Phosphate Injection [see Overdosage (10)]. Monitor patients for signs and symptoms of neurologic toxicity during and after treatment with Fludarabine Phosphate Injection.

Consider delaying or discontinuing Fludarabine Phosphate Injection if neurotoxicity occurs. Do not administer Fludarabine Phosphate Injection at doses higher than the recommended dose. Advise patients that Fludarabine Phosphate Injection may reduce the ability to drive or use mechanical equipment, since fatigue, weakness, visual disturbances, confusion, agitation, or seizures may occur.

5.2 Myelosuppression

5.2 Myelosuppression Fludarabine phosphate can cause severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia, or anemia. Cases of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported. The median time to nadir of counts was approximately 13 days (range, 3 to 25 days) for granulocytes and 16 days (range, 2 to 32 days) for platelets.

The duration of the cytopenia in reported cases has ranged from approximately 2 months to approximately 1 year. Monitor complete blood counts at baseline, prior to and during each treatment cycle, and as clinically needed. Consider dosage delays, dose reductions, or permanent discontinuation if recovery has not occurred by the first day of the next scheduled cycle.

5.3 Autoimmune Cytopenias

5.3 Autoimmune Cytopenias Life-threatening and fatal autoimmune hemolytic anemia, autoimmune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia can occur in patients treated with fludarabine phosphate with or without a previous history of autoimmune hemolytic anemia or a positive Coombs’ test. The majority of patients rechallenged with fludarabine phosphate developed a recurrence in the hemolytic process.

The mechanism(s) which predispose patients to the development of this complication has not been identified. Closely monitor patients during treatment with Fludarabine Phosphate Injection for autoimmune cytopenias and manage as clinically indicated.

5.4 Transfusion Associated Graft-Versus-Host Disease

5.4 Transfusion Associated Graft-Versus-Host Disease Transfusion-associated graft-versus-host disease has been observed after transfusion of non-irradiated blood in patients treated with fludarabine phosphate. Fatal outcome as a consequence of this disease has been reported. Therefore, to minimize the risk of transfusion-associated graft-versus-host disease, patients who require blood transfusion and who are undergoing, or who have received, treatment with Fludarabine Phosphate Injection should receive irradiated blood only.

5.5 Tumor Lysis Syndrome

5.5 Tumor Lysis Syndrome Tumor lysis syndrome (TLS) can occur in patients treated with Fludarabine Phosphate Injection. TLS has been reported in patients with CLL who have large tumor burdens and can occur as early as the first week of treatment. Closely monitor patients at risk for TLS, consider appropriate prophylaxis including hydration, and manage as clinically indicated.

5.6 Pulmonary Toxicity in Patients with CLL When

5.6 Pulmonary Toxicity in Patients with CLL When Fludarabine Phosphate is Used with Pentostatin In clinical trials, patients experienced fatal pulmonary toxicity when treated with fludarabine phosphate and pentostatin for refractory CLL. Avoid concomitant use of Fludarabine Phosphate Injection with pentostatin [see Drug Interactions (7.1)].

5.7 Vaccination

5.7 Vaccination During and after treatment with Fludarabine Phosphate Injection, avoid vaccination with live vaccines.

5.8 Embryo-Fetal Toxicity

5.8 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, Fludarabine Phosphate Injection can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of fludarabine phosphate to pregnant animals during organogenesis resulted in adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities at maternal doses below (rabbits) and above (rats) those in patients at the recommended human dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Fludarabine Phosphate Injection and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Fludarabine Phosphate Injection and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].

Drug interactions

Drug interactions (US label) US FDA label
7.1 Pentostatin

7.1 Pentostatin Avoid use of Fludarabine Phosphate Injection in combination with pentostatin due to the risk of severe and fatal pulmonary toxicity [see Warnings and Precautions (5.6)]

7.1 Pentostatin

7.1 Pentostatin Avoid use of Fludarabine Phosphate Injection in combination with pentostatin due to the risk of severe and fatal pulmonary toxicity [see Warnings and Precautions (5.6)]

Adverse reactions

Adverse reactions (US label) US FDA label

The following clinically significant adverse reactions are described elsewhere in the labeling: Neurologic Toxicities [see Warnings and Precautions (5.1)] Myelosuppression [see Warnings and Precautions (5.2)] Autoimmune Cytopenias [see Warnings and Precautions (5.3)] Transfusion Associated Graft-Versus-Host Disease [see Warnings and Precautions (5.4)] Tumor Lysis Syndrome [see Warnings and Precautions (5.5)] The most common adverse reactions (≥ 20%) are myelosuppression (neutropenia, thrombocytopenia, or anemia), fever, infection, nausea and vomiting, weakness, and pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hisun Pharmaceuticals USA, Inc. at 1-855-554-4786 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. B-cell Chronic Lymphocytic Leukemia Combination with Cyclophosphamide and Rituximab The safety of Fludarabine Phosphate Injection for the treatment of adults with B-cell CLL as a component of a combination regimen was derived from the published literature [see Clinical Studies (14)].

The safety of Fludarabine Phosphate Injection for the treatment of adults with B-cell CLL as a component of a combination regimen was consistent with the known safety profile of fludarabine phosphate. Single Agent The safety of fludarabine phosphate was evaluated in two single-arm open-label studies (MDAH and SWOG) in adult patients (n=133) with CLL refractory to at least one prior alkylating-agent containing regimen [see Clinical Studies (14)].

In these two clinical trials, 22% of the patients treated with fludarabine phosphate had fatal adverse reactions, with approximately 50% of these due to infection. Serious and fatal infections, including opportunistic and reactivation of latent viral infections such as Varicella-Zoster Virus (VZV; herpes zoster), Epstein-Barr Virus (EPV), and John Cunningham (JC) virus (progressive multifocal leukoencephalopathy) occurred in patients treated with fludarabine phosphate.

Hematologic adverse reactions, including neutropenia (Grade 4: 59%), thrombocytopenia (55%), and anemia (55%) occurred in a majority of the CLL patients treated with fludarabine phosphate. The most common adverse reactions (≥ 20%) occurring in patients treated with fludarabine in the MDAH and SWOG trials (n=133) were myelosuppression (neutropenia, thrombocytopenia, or anemia), fever, infection, nausea and vomiting, weakness, and pain.

Table 2 summarizes the non-hematologic adverse reactions in the MDAH and SWOG studies. Table 2: Non-Hematologic Adverse Reactions (≥ 5%) in CLL Patients Treated with Fludarabine in the MDAH and SWOG Studies Adverse Reactions MDAH (N=101) % SWOG (N=32) % General Fever 60 69 Pain 20 22 Fatigue 10 38 Chills 11 19 Malaise 8 6 Diaphoresis 1 13 Infection Infection 33 44 Pneumonia 16 22 Upper respiratory infection 2 16 Urinary infection 2 15 Sinusitis 5 0 Pharyngitis 0 9 Gastrointestinal Nausea/Vomiting 36 31 Anorexia 7 34 Diarrhea 15 13 Stomatitis 9 0 Gastrointestinal bleeding 3 13 Ne urological Weakness 9 65 Paresthesia 4 12 Visual disturbance 3 15 Hearing loss 2 6 P ulmonary Cough 10 44 Dyspnea 9 22 Allergic pneumonitis 0 6 Hemoptysis 1 6 Skin and Subcutaneous Rash 15 15 C ardiovascular Edema 8 19 Angina 0 6 M usculoskeletal Myalgia 4 16 Endocrine Hyperglycemia 1 6 Clinically relevant adverse reactions in < 5% of patients who received fludarabine phosphate included the following: General: Headache, hemorrhage, tumor lysis syndrome (hyperuricemia, hyperphosphatemia, hypocalcemia, metabolic acidosis, hyperkalemia, hematuria, urate crystalluria, flank pain, renal failure) Blood and Lymphatic: Bone marrow fibrosis, thrombocytopenia/ITP, Evans syndrome, acquired hemophilia Cardiovascular: Congestive heart failure, arrhythmia, supraventricular tachycardia, myocardial infarction, transient ischemic attack, pericardial effusion Gastrointestinal: Esophagitis, mucositis, constipation, dysphagia, pancreatic enzyme increase Genitourinary: Dysuria, hematuria, renal failure, abnormal renal function test, proteinuria, hesitancy, hemorrhagic cystitis Hepatobiliary: Liver failure, ALT/AST elevation, cholelithiasis Immune System: Anaphylaxis Infection: VZR (herpes zoster), EBV (lymphoproliferative disorders), JC virus (progressive multifocal leukoencephalopathy) Musculoskeletal: Osteoporosis, arthralgia Neoplasms: tumor flare, skin cancer Neurological: Sleep disorder, depression, cerebellar syndrome, impaired mentation, agitation, confusion, seizures, optic neuritis, optic neuropathy, blindness and coma, peripheral neuropathy, cerebral hemorrhage Pulmonary: Epistaxis, bronchitis, hypoxia, interstitial pulmonary infiltrate Renal &Urinary: Dehydration Skin and Subcutaneous Tissue: Alopecia, pruritis, seborrhea; erythema multiforme, Steven-Johnson syndrome, toxic epidermal necrolysis, pemphigus (some fatal cases) Vascular: Deep venous thrombosis, phlebitis, aneurysm, cerebrovascular accident The following adverse reactions have been identified during postapproval use of fludarabine phosphate.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic: Bone marrow hypoplasia or aplasia resulting in pancytopenia (range: 2 months to 12 months after treatment initiation; some fatal); myelodysplastic syndrome and acute myeloid leukemia Infection: Progressive multifocal leukoencephalopathy (range: 3 weeks to one year after treatment initiation; some fatal) Pulmonary: Acute Respiratory Distress Syndrome (ARDS), respiratory distress, pulmonary hemorrhage, pulmonary fibrosis, pneumonitis, respiratory failure

Adverse reaction frequency tables (US label) US FDA label
Adverse Reactions MDAH (N=101) % SWOG (N=32) %
General
Fever 60 69
Pain 20 22
Fatigue 10 38
Chills 11 19
Malaise 8 6
Diaphoresis 1 13
Infection
Infection 33 44
Pneumonia 16 22
Upper respiratory infection 2 16
Urinary infection 2 15
Sinusitis 5 0
Pharyngitis 0 9
Gastrointestinal
Nausea/Vomiting 36 31
Anorexia 7 34
Diarrhea 15 13
Stomatitis 9 0
Gastrointestinal bleeding 3 13
Ne urological
Weakness 9 65
Paresthesia 4 12
Visual disturbance 3 15
Hearing loss 2 6
P ulmonary
Cough 10 44
Dyspnea 9 22
Allergic pneumonitis 0 6
Hemoptysis 1 6
Skin and Subcutaneous
Rash 15 15
C ardiovascular
Edema 8 19
Angina 0 6
M usculoskeletal
Myalgia 4 16
Endocrine
Hyperglycemia 1 6

Mechanism of action

Fludarabine phosphate is rapidly converted to active 2-fluoro-ara-ATP [see Clinical Pharmacology (12.3)], which appears to inhibit DNA synthesis through inhibition of DNA polymerase alpha, ribonucleotide reductase and DNA primase.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

The degree of absolute granulocyte count nadir is correlated with increased area under the concentration x time curve (AUC); however, the exposure-response relationship and time-course of pharmacodynamic response of fludarabine have not been fully characterized.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

E limination The terminal half-life of 2-fluoro-ara-A was approximately 20 hours.

Renal clearance represents approximately 40% of the total body clearance.

Pharmacokinetics (US label) US FDA label

Fludarabine phosphate is a prodrug. It is rapidly converted to its active metabolite, 2-fluoro-ara-A which is the focus of the pharmacokinetic characterization. 2-fluoro-ara-A plasma trough concentration accumulated 2-fold. D istribution Plasma protein binding ranged between 19% and 29% in vitro. E limination The terminal half-life of 2-fluoro-ara-A was approximately 20 hours.

The total body clearance of 2-fluoro-ara-A correlated with the creatinine clearance. Renal clearance represents approximately 40% of the total body clearance. Me tabolism Fludarabine phosphate is dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Fludarabine Phosphate · Hisun Pharmaceuticals USA, Inc. [US FDA-approved label, version 7, September 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=291f6ee2-f5d2-ae6c-e063-6294a90a5951
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .